Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma [Phase 3]
A Phase 3 clinical trial is evaluating golidocitinib versus placebo as maintenance therapy for peripheral T-cell lymphoma and is currently r…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma [Phase 1]
Phase 1 trial evaluating a four-drug regimen (romidepsin, gemcitabine, dexamethasone, cisplatin) in peripheral T-cell lymphoma and diffuse l…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma [Phase 1, Phase 2]
Phase I/II study of ASTX660 in relapsed or refractory T-cell lymphomas has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) [Phase 1]
Phase 1 study assessing Tolinapant with oral decitabine/cedazuridine and decitabine/cedazuridine alone in relapsed/refractory peripheral T-c…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. [Phase 2]
Phase 2 trial update for Bosmolisib (BR101801) in relapsed/refractory Peripheral T cell lymphoma; the study is currently not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers [Phase 1]
A Phase 1 safety study of PF-08046045/SGN-35T sponsored by Seagen has been terminated in adults with advanced lymphomas and Hodgkin disease.
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas [Phase 1, Phase 2]
Results from a Phase 1/2 study of ALRN-6924 in patients with advanced solid tumors and lymphomas have been posted after completion of the tr…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ATG-010 in combination with chemotherapy with maintenance ATG-010 in Peripheral T-cell lymphoma and natural kil…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) [Phase 2]
Clinical trial update indicates completion of the Phase 2 JACKPOT27 study of AZD4205 for relapsed or refractory peripheral T-cell lymphoma c…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas [Phase 3]
Phase 3 trial updating the role of Brentuximab plus etoposide as first-line therapy for peripheral T-cell lymphoma; study is currently enrol…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 1]
Phase 1 trial evaluating parsaclisib combined with chidamide for relapsed/refractory peripheral T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]
This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has comple…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Romidepsin Maintenance After Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial update on romidepsin as maintenance therapy after allogeneic stem cell transplantation. The study status is completed and incl…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL [Phase 2]
A Phase 2 study evaluating AFM13 in combination with AB-101 for relapsed or refractory Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine [Phase 2]
Phase 2 study of brentuximab vedotin in relapsed/refractory peripheral T-cell lymphoma treated with gemcitabine has completed.
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) [Phase 2]
A Phase 2 clinical trial (JACKPOT26) evaluating AZD4205 in Peripheral T-cell Lymphoma after first-line therapy has completed.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies [Phase 1]
Phase 1 trial evaluating a combination of romidepsin, CC-486 (oral azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refract…
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD7 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell malignancies has completed, assessing safet…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
A completed observational study in Japanese patients with Peripheral T-cell Lymphoma who received second-line therapy.
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression [Phase 2]
This is a Phase 2 frontline study report of brentuximab vedotin combined with CHP for peripheral T-cell lymphoma with low CD30 expression; r…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating decitabine with gemcitabine and oxaliplatin for relapsed/refractory peripheral T-cell lymphoma has been terminate…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) [Phase 1, Phase 2]
Results from the Phase 1/2 JACKPOT8 trial of the oral JAK inhibitor AZD4205 as monotherapy in relapsed or refractory peripheral T-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors [Phase 1]
Phase 1 trial of KT-333 in adults with refractory lymphomas and solid tumors reports safety, pharmacokinetics, pharmacodynamics, and prelimi…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]
This update reports the results of a Phase 2 study of duvelisib in participants with relapsed or refractory peripheral T-cell lymphoma. The …